EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback